PRCT rises as Wall Street slips; investors look again at Aquablation
PROCEPT BioRobotics shares rose 0.6% to $28.29 in early Thursday trading, outperforming broader medical device stocks as Wall Street opened lower. The move follows the American Urological Association’s strengthened recommendation for Aquablation therapy. PROCEPT reported Q1 revenue of $83.1 million, up 20%, but posted a wider net loss of $31.6 million. The company reaffirmed 2026 revenue guidance of $390–$410 million.
